Treatment of alcohol-use disorders

The Lancet

Volumn 373, Issue 9674, 2009, Pages 1519-

  Ameisen, Olivier ^a  

^a Psychologue Psychanalyste   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BACLOFEN; DISULFIRAM; NALTREXONE; TOPIRAMATE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER METABOLISM; MORTALITY; NONHUMAN; PRIORITY JOURNAL;

EID: 65349131939     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60847-3     Document Type: Letter

References (5)

1. Schuckit M.A. Alcohol-use disorders. Lancet 373 (2009) 492-501
2. Pessione F., Ramond M.J., Peters L., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis: effect of alcoholic hepatitis, smoking and abstinence. Liver Int 23 (2003) 45-53
3. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370 (2007) 1915-1922
4. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40 (2005) 147-150
5. Ameisen O. Naltrexone for alcohol dependency. JAMA 294 (2005) 899-900